1. Scrip
  2. >>New Products

Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals

 
• By Mandy Jackson

Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication. 

White lung cancer awareness ribbon and lung symbol on red background. November lung cancer awareness month. Healthcare and medicine concept.
ASCO results show durable efficacy in first-line lung cancer • Source: Shutterstock

Having faced defeat with Opdivo (nivolumab) monotherapy, Bristol-Myers Squibb Co. has pinned its hopes for taking back some share of the lung cancer market lost to Merck & Co. Inc.’s Keytruda (pembrolizumab) to combination use of its PD-1 inhibitor with its CTLA-4 inhibitor Yervoy (ipilimumab) based on results from the CheckMate-227 and CheckMate-9LA studies. Now the company stands ready to deliver on that promise, with the US Food and Drug Administration approval on 15 May of Opdivo plus Yervoy in the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression of 1% or more and no ALK or EGFR alterations.

Three-year data testing Opdivo plus Yervoy versus chemotherapy in the CheckMate-227 clinical trial – the study that supported the new approval – and the first detailed results from the CheckMate-9LA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Scrip

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.